NCT03608566Unknown不适用
The Russian Registry of Patients With Severe Asthma to Collect Anonymous Long-term Evidence
Interregional Public Organization, Russian Respiratory Society1 个研究点 分布在 1 个国家目标入组 7,000 人开始时间: 2018年3月30日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 7,000
- 试验地点
- 1
- 主要终点
- • Percentage of patients with severe asthma according frequency of exacerbations at the time of study enrollment
研究概览
简要总结
The Russian Severe Asthma Registry is a Russian initiative to collect anonymous long-term evidence for patients with severe asthma in Russia
详细描述
The Russian Severe Asthma Registry is a Russian initiative to collect anonymous long-term evidence for patients with severe asthma in Russia. The RSAR initiative is realized under the efforts of the Interregional Public Organization "Russian Respiratory Society" and LLC "RSMI" with the sponsorship of "AstraZeneca Pharmaceuticals" LLC.
The developed RSAR electronic database is a Russian software product that meets the current requirements of the Russian legislation in the field of working with personal data and the implementation of similar observational studies.
Participating researchers also agree to grant access and share anonymous data at the patient level as part of the work to implement the RSAR initiative. Participants will provide high-quality data for the development of data sets for research, approved by the Russian Respiratory Society (RPO), which has priority in owning and implementation in scientific field of the gained data. Based on ethical, legal and regulatory authorizations, anonymous data will be collected in the Central Database (CDB) on respiratory diseases (referred to here as the RSAR database) to create sets of important data and the necessary analysis. CDB is part of the software "Medical online platform ROSMED.INFO".
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 12 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients aged 12 years or older.
- •Patients with confirmed diagnosis of severe asthma.
- •Patients receiving treatment according to GINA step 5 or uncontrolled for 4 step. Uncontrolled patients are defined as having symptoms of severe asthma or frequent exacerbations .
- •Signed informed consent.
排除标准
- •Patients currently participating in clinical trials at the time of enrolment
- •Intermittent, mild, moderate BA, before verification of the diagnosis.
- •Diseases of the respiratory system, such as tuberculosis, sarcoidosis, IPF, lung cancer.
- •Vasculitis, systemic connective tissue diseases.
- •Neoplasm.
- •Written refusal of the patient to participate in the study after signing an informed consent.
结局指标
主要结局
• Percentage of patients with severe asthma according frequency of exacerbations at the time of study enrollment
时间窗: 03.2018 till 11.2022.
Percentage of patients with severe asthma according frequency of exacerbations (1, 2, ≥3 exacerbations) at the time of study enrollment
次要结局
- • Percentage of patients with severe asthma according frequency of exacerbations at the 1 year of follow-up;(03.2019 till 11.2022.)
- Percentage of patients with severe asthma according frequency of exacerbations at the 2 year of follow-up;(03.2020 till 11.2022.)
- • Percentage of patients with severe asthma according frequency of exacerbations at the 3 year of follow-up;(03.2021 till 11.2022.)
- • Percentage of patients with severe asthma according frequency of exacerbations (1, 2, ≥3 exacerbations) at the 4 year of follow-up;(03.2022 till 11.2022.)
- • Percentage of patients with severe asthma according concomitant diseases at the time of study enrollment(03.2018 till 11.2022.)
- • Percentage of patients with severe asthma according concomitant diseases at the 1year of follow-up;(03.2019 till 11.2022.)
- • Percentage of patients with severe asthma according concomitant diseases at the 2 year of follow-up;(03.2020 till 11.2022)
- • Percentage of patients with severe asthma according concomitant diseases at the 3 year of follow-up;(03.2021 till 11.2022)
- • Percentage of patients with severe asthma according concomitant diseases at the 4 year of follow-up;(03.2022 till 11.2022)
- • • Percentage of patients with severe asthma according to parameters: age at the time of study enrollment;(03.2018 till 11.2022)
- • • Percentage of patients with severe asthma according to parameters: sex at the time of study enrollment;(03.2018 till 11.2022)
- • Percentage of patients with severe asthma with different phenotypes in terms of parameters: IgE (IU/ml) at the time of enrollment(03.2018 till 11.2022)
- • Percentage of patients with severe asthma with different phenotypes in terms of parameters: IgE (IU/ml) at the 1year of follow-up;(03.2019 till 11.2022)
- • Percentage of patients with severe asthma with different phenotypes in terms of parameters: IgE (IU/ml) at the 2year of follow-up;(03.2020 till 11.2022)
- • Percentage of patients with severe asthma with different phenotypes in terms of parameters: IgE (IU/ml) at the 3 year of follow-up;(03.2021 till 11.2022)
- • Percentage of patients with severe asthma with different phenotypes in terms of parameters: IgE (IU/ml) at the 4 year of follow-up;(03.2022 till 11.2022)
- • Percentage of patients with severe asthma with different phenotypes in terms of eosinophil levels in absolute values in complete blood count at the time of enrollment;(03.2018 till 11.2022)
- • Percentage of patients with severe asthma with different phenotypes in terms of eosinophil levels in absolute values in complete blood count at the 1 year of follow-up;(03.2019 till 11.2022)
- • Percentage of patients with severe asthma with different phenotypes in terms of eosinophil levels in absolute values in complete blood count at the 2 year of follow-up;(03.2020 till 11.2022)
- • Parameters of FVC (liters, percentage of predicted) before bronchodilator in patients with severe asthma at the 1year of follow-up;(03.2019 till 11.2022)
- • Parameters of FEV1 (liters, percentage of predicted) (the mean value, the standard deviation) post bronchodilator in patients with severe asthma at the 1 year of follow-up;(03.2019 till 11.2022)
- • Parameters of FVC (liters, percentage of predicted) (the mean value, the standard deviation) post bronchodilator in patients with severe asthma at the 1year of follow-up;(03.2019 till 11.2022)
- • Parameters of FEV1 (liters, percentage of predicted) before bronchodilator in patients with severe asthma at the 2 year of follow-up;(03.2020 till 11.2022)
- • Parameters of FVC (liters, percentage of predicted) before bronchodilator in patients with severe asthma at the 2year of follow-up;(03.2020 till 11.2022)
- • Parameters of FEV1 (liters, percentage of predicted) post bronchodilator in patients with severe asthma at the 2 year of follow-up;(03.2020 till 11.2022)
- • Parameters of FVC (liters, percentage of predicted) post bronchodilator in patients with severe asthma at the 2year of follow-up;(03.2020 till 11.2022)
- • Percentage of patients with severe asthma with different phenotypes in terms of eosinophil levels in absolute values in complete blood count at the 3 year of follow-up;(03.2021 till 11.2022)
- • Percentage of patients with severe asthma with different phenotypes in terms of eosinophil levels in absolute values in complete blood count at the 4 year of follow-up;(03.2022 till 11.2022)
- • The parameters of body mass index in the patients with severe asthma at the time of study enrollment;(03.2018 till 11.2022)
- • Parameters of FVC (liters, percentage of predicted) before bronchodilator in patients with severe asthma at the 3year of follow-up(03.2021 till 11.2022)
- • Percentage of patients with severe asthma in the parameters: of smoking at the time of study enrollment;(03.2018 till 11.2022)
- • Percentage of patients with severe asthma in the parameters: of professional history at the time of study enrollment;(03.2018 till 11.2022)
- • Percentage of patients with severe asthma in the parameters: of family history at the time of study enrollment;(03.2018 till 11.2022)
- • Parameters of FEV1 (liters, percentage of predicted) before bronchodilator in patients with severe asthma at the time of study enrollment;(03.2018 till 11.2022)
- • Parameters of FVC (liters, percentage of predicted)before bronchodilator in patients with severe asthma at the time of study enrollment(03.2018 till 11.2022)
- • Parameters of FEV1 (liters, percentage of predicted) post bronchodilator in patients with severe asthma at the time of study enrollment;(03.2018 till 11.2022)
- • Parameters of FVC (liters, percentage of predicted) post bronchodilator in patients with severe asthma at the time of study enrollment;(03.2018 till 11.2022)
- • Parameters of FEV1 (liters, percentage of predicted) before bronchodilator in patients with severe asthma at the 1 year of follow-up(03.2019 till 11.2022)
- • Parameters of FEV1 (liters, percentage of predicted) post bronchodilator in patients with severe asthma at the 3 year of follow-up(03.2021 till 11.2022)
- • Parameters of FEV1 (liters, percentage of predicted) before bronchodilator in patients with severe asthma at the 3 year of follow-up(03.2021 till 11.2022)
- • Parameters of FVC (liters, percentage of predicted) post bronchodilator in patients with severe asthma at the 3year of follow-up(03.2021 till 11.2022)
- • Parameters of FEV1 (liters, percentage of predicted) before bronchodilator in patients with severe asthma at the 4 year of follow-up(03.2022 till 11.2022)
- • Parameters of FVC (liters, percentage of predicted) before bronchodilator in patients with severe asthma at the 4 year of follow-up(03.2022 till 11.2022)
- • Parameters of FEV1 (liters, percentage of predicted) post bronchodilator in patients with severe asthma at the 4 year of follow-up;(03.2022 till 11.2022)
- • Parameters of FVC (liters, percentage of predicted) post bronchodilator in patients with severe asthma at the 4 year of follow-up;(03.2022 till 11.2022)
- • Parameters of the analysis of the questionnaire ACQ-6 in patients with severe asthma at the time of study enrollment;(03.2018 till 11.2022)
- • Parameters of the analysis of the questionnaire ACQ-6 in patients with severe asthma at the 1 year of follow-up;(03.2019 till 11.2022)
- • Parameters of the analysis of the questionnaire ACQ-6 in patients with severe asthma at the 2 year of follow-up;(03.2020 till 11.2022)
- • Parameters of the analysis of the questionnaire ACQ-6 in patients with severe asthma at the 3 year of follow-up;(03.2021 till 11.2022)
- • Parameters of the analysis of the questionnaire ACQ-6 in patients with severe asthma at the 4 year of follow-up;(03.2022 till 11.2022)
- • Number of exacerbations requiring medical attention (outpatient prescription of systemic corticosteroids) in patients with severe asthma at the time of study enrollment;(03.2018 till 11.2022)
- • Number of exacerbations requiring medical attention (outpatient prescription of systemic corticosteroids) in patients with severe asthma at the 1year of follow-up;(03.2019 till 11.2022)
- • Number of exacerbations requiring medical attention (outpatient prescription of systemic corticosteroids) in patients with severe asthma at the 2year of follow-up;(03.2020 till 11.2022)
- • Number of exacerbations requiring medical attention (outpatient prescription of systemic corticosteroids) in patients with severe asthma at the 3 year of follow-up;(03.2021 till 11.2022)
- • Number of exacerbations requiring medical attention (outpatient prescription of systemic corticosteroids) in patients with severe asthma at the 4 year of follow-up;(03.2022 till 11.2022)
- • Number of hospitalizations in patients with severe asthma at the time of inclusion in the study;(03.2018 till 11.2022)
- • Number of hospitalizations in patients with severe asthma at the time of inclusion in the 1 year of follow-up;(03.2019 till 11.2022)
- • Number of hospitalizations in patients with severe asthma at the time of inclusion in the 2 year of follow-up;(03.2020 till 11.2022)
- • Number of hospitalizations in patients with severe asthma at the time of inclusion in the 3 year of follow-up;(03.2021 till 11.2022)
- • Number of hospitalizations in patients with severe asthma at the time of inclusion in the 4 year of follow-up;(03.2022 till 11.2022)
- • Percentage of patients with severe asthma taking high doses of ICS/LABA, ICS/LABA+LAMA as maintenance therapy, biologics at the time of study enrollment;(03.2018 till 11.2022)
- • Percentage of patients with severe asthma taking high doses of ICS/LABA, ICS/LABA+LAMA as maintenance therapy, biologics at the 1 year of follow-up;(03.2019 till 11.2022)
- • Percentage of patients with severe asthma taking high doses of ICS/LABA, ICS/LABA+LAMA as maintenance therapy, biologics at the 2 year of follow-up;(03.2020 till 11.2022)
- • Percentage of patients with severe asthma taking high doses of ICS/LABA, ICS/LABA+LAMA as maintenance therapy, biologics at the 3 year of follow-up;(03.2021 till 11.2022)
- • Percentage of patients with severe asthma taking high doses of ICS/LABA, ICS/LABA+LAMA as maintenance therapy, biologics at the 4 year of follow-up;(03.2022 till 11.2022)
- • Percentage of patients with severe asthma taking OCS as a maintenance therapy at the time of study enrollment;(03.2018 till 11.2022)
- • Percentage of patients with severe asthma taking OCS as a maintenance therapy at the 1 year of follow-up;(03.2019 till 11.2022)
- • Percentage of patients with severe asthma taking OCS as a maintenance therapy at the 2 year of follow-up;(03.2020 till 11.2022)
- • Percentage of patients with severe asthma taking OCS as a maintenance therapy at the 3 year of follow-up;(03.2021 till 11.2022)
- • Percentage of patients with severe asthma taking OCS as a maintenance therapy at the 4 year of follow-up;(03.2022 till 11.2022)
- • Percentage of patients with severe asthma who have been changed therapy to 1 year of follow-up;(03.2019 till 11.2022)
- • Percentage of patients with severe asthma who have been changed therapy to 2 year of follow-up;(03.2020 till 11.2022)
- • Percentage of patients with severe asthma who have been changed therapy to 3 year of follow-up;(03.2021 till 11.2022)
- • Percentage of patients with severe asthma who have been changed therapy to 4 year of follow-up;(03.2022 till 11.2022)
- • Percentage of patients with severe asthma who called for emergency medical care for asthma at the 1 year of follow-up;(03.2019 till 11.2022)
- • Percentage of patients with severe asthma who called for emergency medical care for asthma at the 2 year of follow-up;(03.2020 till 11.2022)
- • Percentage of patients with severe asthma who called for emergency medical care for asthma at the 3 year of follow-up;(03.2021 till 11.2022)
- • Percentage of patients with severe asthma who called for emergency medical care for asthma at the 4 year of follow-up;(03.2022 till 11.2022)
- • Percentage of patients with severe asthma who had disability sheets for asthma at the 1year of follow-up;(03.2019 till 11.2022)
- • Percentage of patients with severe asthma who had disability sheets for asthma at the 2 year of follow-up;(03.2020 till 11.2022)
- • Percentage of patients with severe asthma who had disability sheets for asthma at the 3 year of follow-up;(03.2021 till 11.2022)
- • Percentage of patients with severe asthma who had disability sheets for asthma at the 4 year of follow-up;(03.2022 till 11.2022)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
不适用
Severe Asthma Network ItalySevere AsthmaNCT06625216Società Italiana di Allergologia, Asma e Immunologia Clinica5,000
招募中
不适用
Registry of Asthma Characterization and Recruitment 3 (RACR3)AsthmaNCT05272241National Institute of Allergy and Infectious Diseases (NIAID)1,500
招募中
不适用
Register Schweres Asthma - German Asthma Net e.V.Severe AsthmaNCT06035289German Asthma Net e.V.4,500
招募中
不适用
Taiwan Severe Asthma Biologic RegistryPulmonary DiseaseAsthmaNCT06456450Taichung Veterans General Hospital500
招募中
不适用
Co-morbidity and Refractory Asthma - UK Severe Asthma RegistryAsthmaNCT04553276Queen's University, Belfast4,800